Prot #J2J-MC-JZLH: EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with

Project: Research project

Project Details

Effective start/end date11/16/2311/16/26


  • Lilly USA, LLC (Prot #J2J-MC-JZLH)